1-155235790-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 4P and 1B. PM1PM2BP4
The NM_000157.4(GBA1):c.1279G>A(p.Glu427Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000193 in 1,614,180 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. E427E) has been classified as Likely benign.
Frequency
Consequence
NM_000157.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GBA1 | NM_000157.4 | c.1279G>A | p.Glu427Lys | missense_variant | 9/11 | ENST00000368373.8 | NP_000148.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GBA1 | ENST00000368373.8 | c.1279G>A | p.Glu427Lys | missense_variant | 9/11 | 1 | NM_000157.4 | ENSP00000357357.3 |
Frequencies
GnomAD3 genomes AF: 0.000151 AC: 23AN: 152178Hom.: 0 Cov.: 30
GnomAD3 exomes AF: 0.000175 AC: 44AN: 251460Hom.: 0 AF XY: 0.000177 AC XY: 24AN XY: 135910
GnomAD4 exome AF: 0.000197 AC: 288AN: 1461884Hom.: 0 Cov.: 32 AF XY: 0.000188 AC XY: 137AN XY: 727246
GnomAD4 genome AF: 0.000151 AC: 23AN: 152296Hom.: 0 Cov.: 30 AF XY: 0.000161 AC XY: 12AN XY: 74464
ClinVar
Submissions by phenotype
not provided Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Sep 04, 2024 | Reported in patients with Parkinson disease or dementia with Lewy bodies; however, additional information was not provided (PMID: 31996268, 25249066, 32618053, 23588557, 27717005, 34867278, 37750340); Reported in a patient with low levels of GBA activity who harbored a pathogenic variant on the opposite allele (in trans); however, the unaffected sister also carried both variants (PMID: 22820396); Published functional studies by in vitro expression studies demonstrate that the mutant protein retained 48% of wild type activity (PMID: 22820396); In silico analysis indicates that this missense variant does not alter protein structure/function; Also known as p.E388K; This variant is associated with the following publications: (PMID: 23035075, 25957717, 30302829, 28890071, 18160183, 27094865, 23225227, 27717005, 32618053, 23588557, 25249066, 33881531, Terranova2021[Article], 32658388, 19433657, 34227697, 31672490, 22820396, 34867278, 37750340, 31996268, 37996455, 35639160, 32540937) - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2023 | GBA1: PM2, PM3:Supporting, PS3:Supporting - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 16, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 06, 2022 | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 427 of the GBA protein (p.Glu427Lys). The frequency data for this variant in the population databases (gnomAD) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This missense change has been observed in individual(s) with clinical features of GBA-related conditions (PMID: 22820396, 23035075, 23588557, 30302829, 32618053, 32658388). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as E388K. ClinVar contains an entry for this variant (Variation ID: 493050). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Experimental studies have shown that this missense change affects GBA function (PMID: 22820396). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 30, 2020 | The c.1279G>A (p.E427K) alteration is located in exon 10 (coding exon 9) of the GBA gene. This alteration results from a G to A substitution at nucleotide position 1279, causing the glutamic acid (E) at amino acid position 427 to be replaced by a lysine (K). The in silico prediction for the p.E427K alteration is inconclusive. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Cogwheel rigidity;C0234379:Resting tremor;C0242422:Parkinsonian disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2017 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at